Anika Therapeutics Inc

Anika Therapeutics Inc. a joint preservation company creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management regenerative solutions sports medicine and bone preserving joint solutions in the United States Europe and internationally. The company develops manufactures and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; Cingal a single-injection OA pain management product to provide both short- and long-term pain relief; and Hyvisc a molecular weight injectable HA veterinary product. The company's joint preservation and restoration product family comprises 150 bone preserving joint technology products including partial joint replacement joint resurfacing and invasive and bone sparing implants which are designed to treat upper and lower extremity orthopedic conditions; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and orthopedic regenerative solutions including Hyalofast and Tactoset. In addition it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including adhesion barrier advanced wound care ear nose and throat products as well as ophthalmic products. The company was founded in 1983 and is headquartered in Bedford Massachusetts.